PROK · Prokidney Corp.
$1.53
-0.07 (-4.08%)
At close · Jul 22
Market Cap
$462.15M
Shares
302.06M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$893K
+1075%
FY2025
Net Income
-$68.99M
-12.7%
FY2025
Operating Margin
-18477.83%
+223201.1pp
FY2025
Diluted EPS
-$0.23
FY2022
Operating Cash Flow
-$120.12M
+4.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $889K | $893K | $76K | — | — | — | |
| $120.7M | $114.12M | $127.67M | $106.71M | $82.07M | — | |
| $48.74M | $51.78M | $56.08M | $44.82M | $70.94M | — | |
| — | $0 | $213K | $213K | $215M | — | |
| — | $6.58M | $5.43M | $3.85M | $3.04M | — | |
| $169.44M | $165.9M | $183.75M | $151.52M | $153.01M | $2.33M | |
| -$168.55M | -$165.01M | -$183.68M | -$151.52M | -$153.01M | -$2.33M | |
| — | -18477.83% | -241678.95% | — | — | — | |
| — | -$158.43M | -$178.24M | -$147.67M | -$149.97M | — | |
| $19K | $4000 | $9000 | $12K | $215K | — | |
| — | — | — | — | — | $8324 | |
| — | $3.42M | $7M | — | — | — | |
| -$156.46M | -$151.2M | -$163.93M | -$129.45M | -$147.24M | — | |
| -$177K | $414K | -$598K | $6M | $896K | — | |
| -$72.29M | -$68.99M | -$61.19M | -$35.47M | -$148.14M | -$2.32M | |
| — | -7725.2% | -80507.89% | — | — | — | |
| -$72.42M | -$69.06M | -$61.19M | -$35.34M | — | — | |
| USD/shares | — | — | — | — | -$0.23 | — |
| USD/shares | — | — | — | — | -$0.23 | — |
| shares | — | — | — | — | 61.54M | — |
| shares | — | — | — | — | 61.54M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $9.5M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.58×
EV/EBIT
—
Biotechnology median 26.67×
P/E (TTM)
—
Biotechnology median 7.06×